youtube_live
Q3 2026 earnings • in 3 days
See detailschevron_right
MEDP:NASDAQ
Medpace Holdings Inc
$619.66
arrow_upward
+0.19%(+1.19) 1D
$619.66
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 19, 4:00:00 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MEDP...
Open
$619.33
High
$625.69
Low
$616.14
Mkt. cap
17.30B
Avg. vol.
250.34K
Volume
247.11K
P/E ratio
36.35
52-wk high
$677.90
52-wk low
$373.00
EPS
$17.05
Beta
1.18
Shares outstanding
27.91M
No. of employees
6K
Open
$619.33
High
$625.69
Low
$616.14
Mkt. cap
17.30B
Avg. vol.
250.34K
Volume
247.11K
P/E ratio
36.35
52-wk high
$677.90
52-wk low
$373.00
EPS
$17.05
Beta
1.18
Shares outstanding
27.91M
No. of employees
6K
News stories
From web sources and news partners
Profile
Medpace Holdings, Inc. is a global clinical research organization based in Cincinnati, Ohio, employing approximately 6,500 people. Operating under a full-service model, the company also offers global central laboratory, imaging and ECG core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
The company started trading stock as a public firm in 2016. Wikipedia
About Medpace Holdings Inc
CEOAugust J. Troendle
Employees6.5K
Founded1992
HeadquartersCincinnati, Ohio, United States
SectorHealth care
Websitemedpace.com
Analyst ratings
Based on 12 analysts giving stock ratings to MEDP in the past 3 months
Hold
Buy
2
Hold
10
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for MEDP in the last 3 months.
Highest
Current $619.66
$700.00 (+12.97%)
Average
$612.10 (-1.22%)
Lowest
$492.00 (-20.60%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Ann Hynes Mizuho Securities | Buy | Maintained | $700.00 | +13% | 10/07/2026 |
Luke Sergott Barclays | Hold | Maintained | $625.00 | +0.9% | 10/07/2026 |
Ryan Halsted RBC Capital | Buy | Maintained | $692.00 | +11.7% | 10/06/2026 |
Kevin Caliendo UBS | Hold | Initiated | $673.00 | +8.6% | 10/02/2026 |
Jailendra Singh Truist Financial | Hold | Maintained | - | - | 09/17/2026 |
David Windley Jefferies | Hold | Maintained | $560.00 | -9.6% | 09/14/2026 |
Sean Dodge BMO Capital | Hold | Maintained | $600.00 | -3.2% | 07/27/2026 |
Eric Coldwell Robert W. Baird | Hold | Maintained | $624.00 | +0.7% | 07/24/2026 |
Charles Rhyee TD Cowen | Hold | Reiterated | $492.00 | -20.6% | 07/23/2026 |
Michael Cherny Leerink Partners | Hold | Maintained | $620.00 | +0.1% | 07/23/2026 |
Justin Bowers Deutsche Bank | Hold | Maintained | $535.00 | -13.7% | 07/23/2026 |
Jared Haase William Blair | Hold | Reiterated | - | - | 07/23/2026 |
Max Smock William Blair | Hold | Reiterated | $393.00 | -36.6% | 04/23/2026 |
Next call in 3 days
Thu, Oct 22, 3:00 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $4.46
Revenue / Est. (USD)
- / 714.44M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 659.90M | 708.45M | 706.60M | 707.33M |
Cost of goods sold | 186.34M | 182.15M | 198.27M | 202.56M |
Cost of revenue | 186.34M | 182.15M | 198.27M | 202.56M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 48.08M | 44.92M | 47.92M | 48.10M |
Operating expense | 331.76M | 373.03M | 366.83M | 357.95M |
Total operating expenses | 518.10M | 555.18M | 565.10M | 560.51M |
Operating income | 141.81M | 153.27M | 141.50M | 146.82M |
Other non operating income | -489.00K | 7.57M | 971.00K | -147.00K |
EBT including unusual items | 142.84M | 156.83M | 147.59M | 151.66M |
EBT excluding unusual items | 142.84M | 156.83M | 147.59M | 151.66M |
Income tax expense | 31.70M | 21.70M | 23.72M | 30.30M |
Effective tax rate | 22.19% | 13.84% | 16.07% | 19.98% |
Other operating expenses | 276.63M | 320.98M | 312.00M | 303.14M |
Net income | 111.14M | 135.13M | 123.87M | 121.36M |
Net profit margin | 16.84% | 19.07% | 17.53% | 17.16% |
Earnings per share | 3.86 | 4.67 | 4.28 | 4.25 |
Interest and investment income | 1.52M | 3.72M | 5.12M | 4.99M |
Interest expense | - | - | - | - |
Net interest expenses | 1.52M | 3.72M | 5.12M | 4.99M |
Depreciation and amortization charges | 6.81M | 6.89M | 6.75M | 6.56M |
EBITDA | 148.86M | 160.40M | 148.41M | 153.53M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1